A smart biotech company could have a great idea for how to use gene editing to develop a new lifesaving therapy – but because of the way licensing deals have been cut by UC-Berkeley and Massachusetts’ Broad Institute, it would never get a chance to try it. That’s the assertion of intellectual property experts in Friday’s issue of the journal Science, who criticize the licensing landscape around the powerful new tool called CRISPR-Cas9, warning it could limit its promise.